CASE DISCUSSION
Biosimilars and Cancer Supportive Care
Presented from India by Dr. Abdul Rahman Agha El Kinge0
Likes
4047
Views
162
Shares
202
Bookmarks
0
Credit Points
0
Learning Hours
0
CPD/CME Points
0
Courses Completed
Case Description
Biosimilars are biological products that are highly similar to and have no clinically meaningful differences from an existing approved reference biologic drug. In cancer supportive care, biosimilars have become increasingly important for managing various aspects of cancer treatment, including...
Case Summary
- Biosimilars are gaining importance due to rising medication costs, which can burden patients, families, and healthcare systems. Maintaining patient access to medication is a priority, and biosimilars offer a potential solution by mitigating financial toxicity and reducing out-of-pocket expenses for patients.
Speaker Profile
Dr. Abdul Rahman Agha El Kinge
Alumni- American University of Beirut Medical CenterConsultant in Medical Oncology, Fakeeh University Hospital, Dubai, United Arab Emirates
Disclosures
Assimilate requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships for anyone with the ability to control the content of this educational activity have been reviewed and mitigated. Others involved in the planning of this activity have no relevant financial relationships.